AUS
NZ
UK
CA
USA
IND
Highlights
- Piper Sandler has increased Ardelyx's target price, while Citigroup and Jefferies Financial Group have adjusted their targets.
- Significant insider transactions include a large purchase by Director David M. Mott and a notable sale by insider David P. Rosenbaum.
- Institutional investors have been actively adjusting their stakes in Ardelyx, with some increasing their holdings significantly.
Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company focused on gastrointestinal and cardiorenal therapeutic areas, has become the subject of revised price targets and ratings in recent reports. Notably, Piper Sandler raised the target price for Ardelyx from $7.00 to $8.00, maintaining a neutral rating on the stock. Meanwhile, Citigroup reduced its price target from $12.00 to $10.00, and Jefferies Financial Group adjusted its objective from $11.00 to $8.00, both offering a more optimistic outlook with a buy rating.
Market sentiment for Ardelyx is reflected in various expert perspectives: three have given hold ratings, while six advocate for buy ratings. As per MarketBeat.com data, the stock maintains an average moderate buy rating, with an average target price of $9.42. Ardelyx shares, opening at $5.47 recently, have demonstrated a variability range over the past year, from a low of $4.32 to a high of $10.13.
Apart from expert scrutiny, Ardelyx has also seen significant insider trading activity. Director David M. Mott expanded his stake in the company, buying 213,300 shares at an average price of $4.67, marking a substantial increase in ownership. Contrarily, insider David P. Rosenbaum sold 27,171 shares at an average price of $6.10. These transactions reflect strategic positioning by insiders, whose buying and selling activities are frequently scrutinized by investors for guidance.
Institutional investments also paint an evolving picture, as major firms alter their holdings in Ardelyx. Millennium Management LLC notably increased its position in Ardelyx by 142.8% during the second quarter, while Rubric Capital Management LP expanded its holdings by 68.5% in the third quarter. Eventide Asset Management LLC and Squarepoint Ops LLC were among the other firms that adjusted their positions, indicating a dynamic investment landscape.
With 58.92% of Ardelyx's stock owned by hedge funds and institutional investors, market movements and sentiments are crucial for stakeholders. While Ardelyx continues to focus on developing treatments for critical medical conditions, market experts and investors remain keenly interested in the stock's performance and strategic developments.
